Trince, a Ghent University spin-off, has pioneered the LumiPore® platform to overcome persistent obstacles in intracellular delivery, a critical process for biological research and therapeutic development. Traditional methods often compromise cell health, but LumiPore® utilizes photoporation to gently and effectively transport various molecules into cells, thereby enhancing the reliability of experimental outcomes and accelerating the development of new treatments.

Breakthroughs in Cell Transfection: The LumiPore® Innovation

Founded in 2021 by Kevin Braeckmans, Philip Mathuis, and Stefaan De Smedt, Trince is dedicated to advancing technologies for introducing substances into cells. Kevin Braeckmans, the current CEO, emphasizes the company's commitment to improving intracellular delivery, particularly for drug development and screening. The core challenge in this field lies in efficiently delivering payloads, such as messenger RNA or gene-editing complexes, into cells without causing damage. While viral vectors are effective, they are costly and have cargo limitations. Electroporation, another common technique, often results in significant cell toxicity and altered cellular characteristics.

LumiPore® stands out as a non-viral alternative, offering both high efficiency and exceptional gentleness. This photoporation-based system employs light-sensitive nanoparticles. These nanoparticles attach to cell membranes and, upon laser illumination, absorb light to generate localized heat. This precise heating creates transient, nanometer-sized pores, allowing external molecules to diffuse into the cell. This highly localized process minimizes cellular impact, ensuring superior cell viability and maintaining cellular health for subsequent biological analyses. Numerous scientific publications from Trince's academic teams have validated this approach, demonstrating its applicability across diverse cell types and payloads while being rapid and efficient.

The platform's gentle nature is particularly beneficial for hard-to-transfect cells like T-cells and stem cells, which are highly sensitive to harsh treatments. LumiPore® significantly increases their survival rates and accelerates recovery, leading to more consistent and reliable biological data. This gentle handling also preserves the natural functions of engineered cells, a crucial factor in cell therapy applications, where maintaining therapeutic efficacy is paramount. Unlike viral vectors, LumiPore® avoids risks such as immunogenic responses or unintended genomic integration, making it a safer physical approach.

Scalability was a fundamental consideration in LumiPore®'s design. The system seamlessly integrates with standard cell culture vessels, including multi-well plates and Petri dishes, requiring only light-transparent consumables. The rapid laser illumination process allows for treating entire well plates in under ten minutes, making it highly suitable for high-throughput screening and automated industrial workflows. Its flexibility extends to various research applications, from CRISPR screens and cell line generation to RNA interference studies and screening biologics. Researchers can adapt the same instrument and workflow for diverse needs, streamlining laboratory operations.

While direct pore size measurement remains challenging due to rapid cellular repair mechanisms, LumiPore® effectively delivers molecules up to hundreds of kilodaltons. The transient pores close within seconds, facilitating efficient cargo entry while preserving membrane integrity. Trince's ongoing research also focuses on optimizing delivery for larger plasmid constructs.

Following significant recognition, including the 2024 Nature Spinoff Prize and the 2026 SLAS Ignite Award, Trince aims to accelerate global commercialization and strengthen its presence in the United States. The company plans a major funding round in 2027 to support its expansion, particularly in integrating the platform into automated drug discovery workflows. Trince emphasizes a partnership-driven approach, working closely with customers to tailor LumiPore® for their specific needs, thereby bridging academic innovation with practical biotechnological solutions.

From a scientific and industrial perspective, Trince's LumiPore® platform represents a substantial leap forward in intracellular delivery. Its ability to efficiently and gently transfect sensitive cells addresses a long-standing bottleneck in drug discovery and cell therapy development. By minimizing cellular stress and preserving functionality, LumiPore® not only improves the quality and reliability of research outcomes but also promises to accelerate the pace at which new, life-saving therapies reach patients. This innovation underscores the immense potential of photoporation to reshape the landscape of biological engineering and therapeutic interventions.